GPAT
GP-Act III Acquisition Corp.
Shell Companies
Market Cap$390M
5Y Perf.+8.2%
Build Your Comparison
Side-by-side financial analysisGPAT
MS
Try popular comparisons:
Stock Comparison
GPAT vs MS
Revenue, margins, valuation, and 5-year total return — side by side.
MS
Morgan Stanley
Financial - Capital Markets
Market Cap$340.97B
5Y Perf.+107.4%
GPAT vs MS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  GPAT |  MS |
|---|---|---|
| Industry | Shell Companies | Financial - Capital Markets |
| Market Cap | $390M | $340.97B |
| Revenue (TTM) | $0.00 | $114.98B |
| Net Income (TTM) | $12M | $16.86B |
| Gross Margin | — | 57.1% |
| Operating Margin | — | 19.1% |
| Forward P/E | 26.4x | 18.0x |
| Total Debt | $400K | $475.56B |
| Cash & Equiv. | $113K | $111.69B |
GPAT vs MS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GPAT
MS
| Stock | Jul 24 | Jun 26 | Return |
|---|---|---|---|
| GP-Act III Acquisit… (GPAT) | 100 | 108.2 | +8.2% |
| Morgan Stanley (MS) | 100 | 207.4 | +107.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GPAT vs MS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MS leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. GP-Act III Acquisition Corp. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇MS emerged as the overall leader. Track its performance:
GPAT
GP-Act III Acquisition Corp.
The Banking Pick
GPAT is the clearest fit if your priority is sleep-well-at-night and bank quality.
- Lower volatility, beta -0.02, Low D/E 0.1%, current ratio 0.30x
- NIM 4.0% vs MS's 0.7%
- Lower D/E ratio (0.1% vs 422.1%)
Best for: sleep-well-at-night and bank quality
MS
Morgan Stanley
The Banking Pick
MS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 11.5%, EPS growth 28.3%
- 8.5% 10Y total return vs GPAT's 8.5%
- Beta 1.40, yield 1.9%, current ratio 1.17x
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  MS | 11.5% NII/revenue growth vs GPAT's -100.0% |
| Value | MS | Lower P/E (18.0x vs 26.4x) |
| Quality / Margins | MS | 14.7% margin vs GPAT's 4.0% |
| Stability / Safety |  GPAT | Lower D/E ratio (0.1% vs 422.1%) |
| Dividends | MS | 1.9% yield; 12-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | MS | +65.3% vs GPAT's +2.4% |
| Efficiency (ROA) | GPAT | 3.9% ROA vs MS's 1.2%, ROIC -0.1% vs 3.1% |
GPAT vs MS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
GPAT vs MS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMSLAGGINGGPAT
GPATGP-Act III Acquisitio…
0leads
MSMorgan Stanley
2leads
6 Total Categories
CATEGORYLEADERvs GPATMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
MS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MS and GPAT operate at a comparable scale, with $115.0B and $0 in trailing revenue.
| Metric | GPATGP-Act III Acquis… | MSMorgan Stanley |
|---|---|---|
| RevenueTrailing 12 months | $0 | $115.0B |
| EBITDAEarnings before interest/tax | -$551,918 | $26.6B |
| Net IncomeAfter-tax profit | $12M | $16.9B |
| Free Cash FlowCash after capex | -$372,225 | -$17.9B |
| Gross MarginGross profit ÷ Revenue | — | +57.1% |
| Operating MarginEBIT ÷ Revenue | — | +19.1% |
| Net MarginNet income ÷ Revenue | — | +14.7% |
| FCF MarginFCF ÷ Revenue | — | -15.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -10.0% | +48.9% |
MS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — GPAT and MS each lead in 1 of 2 comparable metrics.
Valuation Metrics
At 21.0x trailing earnings, MS trades at a 21% valuation discount to GPAT's 26.4x P/E.
| Metric | GPATGP-Act III Acquis… | MSMorgan Stanley |
|---|---|---|
| Market CapShares × price | $390M | $341.0B |
| Enterprise ValueMkt cap + debt − cash | $390M | $704.8B |
| Trailing P/EPrice ÷ TTM EPS | 26.44x | 20.98x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 18.00x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.19x |
| EV / EBITDAEnterprise value multiple | — | 26.49x |
| Price / SalesMarket cap ÷ Revenue | — | 2.97x |
| Price / BookPrice ÷ Book value/share | 1.06x | 3.03x |
| Price / FCFMarket cap ÷ FCF | — | 7.40x |
Evenly matched — GPAT and MS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — GPAT and MS each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
MS delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $4 for GPAT. GPAT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MS's 4.22x. On the Piotroski fundamental quality scale (0–9), MS scores 7/9 vs GPAT's 2/9, reflecting strong financial health.
| Metric | GPATGP-Act III Acquis… | MSMorgan Stanley |
|---|---|---|
| ROE (TTM)Return on equity | +4.1% | +15.3% |
| ROA (TTM)Return on assets | +3.9% | +1.2% |
| ROICReturn on invested capital | -0.1% | +3.1% |
| ROCEReturn on capital employed | -0.2% | +3.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 |
| Debt / EquityFinancial leverage | 0.00x | 4.22x |
| Net DebtTotal debt minus cash | $287,340 | $363.9B |
| Cash & Equiv.Liquid assets | $112,660 | $111.7B |
| Total DebtShort + long-term debt | $400,000 | $475.6B |
| Interest CoverageEBIT ÷ Interest expense | — | 0.45x |
Evenly matched — GPAT and MS each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MS five years ago would be worth $25,467 today (with dividends reinvested), compared to $10,851 for GPAT. Over the past 12 months, MS leads with a +65.3% total return vs GPAT's +2.4%. The 3-year compound annual growth rate (CAGR) favors MS at 37.1% vs GPAT's 2.8% — a key indicator of consistent wealth creation.
| Metric | GPATGP-Act III Acquis… | MSMorgan Stanley |
|---|---|---|
| YTD ReturnYear-to-date | +1.6% | +18.8% |
| 1-Year ReturnPast 12 months | +2.4% | +65.3% |
| 3-Year ReturnCumulative with dividends | +8.5% | +157.5% |
| 5-Year ReturnCumulative with dividends | +8.5% | +154.7% |
| 10-Year ReturnCumulative with dividends | +8.5% | +854.4% |
| CAGR (3Y)Annualised 3-year return | +2.8% | +37.1% |
MS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GPAT and MS each lead in 1 of 2 comparable metrics.
Risk & Volatility
GPAT is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than MS's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MS currently trades 97.7% from its 52-week high vs GPAT's 90.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GPATGP-Act III Acquis… | MSMorgan Stanley |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.02x | 1.40x |
| 52-Week HighHighest price in past year | $12.00 | $219.16 |
| 52-Week LowLowest price in past year | $10.42 | $128.81 |
| % of 52W HighCurrent price vs 52-week peak | +90.3% | +97.7% |
| RSI (14)Momentum oscillator 0–100 | 61.8 | 62.2 |
| Avg Volume (50D)Average daily shares traded | 120K | 4.5M |
Evenly matched — GPAT and MS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
MS is the only dividend payer here at 1.93% yield — a key consideration for income-focused portfolios.
| Metric | GPATGP-Act III Acquis… | MSMorgan Stanley |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $201.25 |
| # AnalystsCovering analysts | — | 52 |
| Dividend YieldAnnual dividend ÷ price | — | +1.9% |
| Dividend StreakConsecutive years of raises | — | 12 |
| Dividend / ShareAnnual DPS | — | $4.14 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
Insufficient data to determine a leader in this category.
Key Takeaway
MS leads in 2 of 6 categories — strongest in Income & Cash Flow and Total Returns. 3 categories are tied.
Best OverallMorgan Stanley (MS)Leads 2 of 6 categories
Loading custom metrics...
GPAT vs MS: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is GPAT or MS a better buy right now?
Morgan Stanley (MS) offers the better valuation at 21.
0x trailing P/E (18. 0x forward), making it the more compelling value choice. Analysts rate Morgan Stanley (MS) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GPAT or MS?
On trailing P/E, Morgan Stanley (MS) is the cheapest at 21.
0x versus GP-Act III Acquisition Corp. at 26. 4x.
03Which is the better long-term investment — GPAT or MS?
Over the past 5 years, Morgan Stanley (MS) delivered a total return of +154.
7%, compared to +8. 5% for GP-Act III Acquisition Corp. (GPAT). Over 10 years, the gap is even starker: MS returned +854. 4% versus GPAT's +8. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GPAT or MS?
By beta (market sensitivity over 5 years), GP-Act III Acquisition Corp.
(GPAT) is the lower-risk stock at -0. 02β versus Morgan Stanley's 1. 40β — meaning MS is approximately -6844% more volatile than GPAT relative to the S&P 500. On balance sheet safety, GP-Act III Acquisition Corp. (GPAT) carries a lower debt/equity ratio of 0% versus 4% for Morgan Stanley — giving it more financial flexibility in a downturn.
05Which is growing faster — GPAT or MS?
On earnings-per-share growth, the picture is similar: Morgan Stanley grew EPS 28.
3% year-over-year, compared to -12. 8% for GP-Act III Acquisition Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GPAT or MS?
Morgan Stanley (MS) is the more profitable company, earning 14.
7% net margin versus 0. 0% for GP-Act III Acquisition Corp. — meaning it keeps 14. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MS leads at 19. 1% versus 0. 0% for GPAT. At the gross margin level — before operating expenses — MS leads at 57. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — GPAT or MS?
In this comparison, MS (1.
9% yield) pays a dividend. GPAT does not pay a meaningful dividend and should not be held primarily for income.
08Is GPAT or MS better for a retirement portfolio?
For long-horizon retirement investors, GP-Act III Acquisition Corp.
(GPAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 02)). Both have compounded well over 10 years (GPAT: +8. 5%, MS: +854. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between GPAT and MS?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
MS pays a dividend while GPAT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.